Edition:
United States

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.51USD
16 Feb 2018
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.52
Open
$3.50
Day's High
$3.67
Day's Low
$3.49
Volume
84,193
Avg. Vol
32,635
52-wk High
$5.11
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Monday, 11 Dec 2017 04:30pm EST 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 08:30am EST 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 09:20am EDT 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Mustang Bio enters lease agreement for production of Car T therapies
Monday, 30 Oct 2017 07:30am EDT 

Oct 30 (Reuters) - Fortress Biotech Inc :Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​.Facility is expected to be operational for production of personalized Car T therapies in 2018​.Has entered into a lease agreement with UMASS Medicine Science Park in Worcester, Massachusetts​.  Full Article

Mustang Bio announces $12.8 mln grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma
Wednesday, 11 Oct 2017 07:30am EDT 

Oct 11 (Reuters) - Fortress Biotech Inc ::Mustang Bio announces $12.8 million grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma.  Full Article

Avenue Therapeutics doses first patient in postoperative pain trial
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics announces dosing of first patient in pivotal Phase 3 clinical trial of intravenous tramadol for the management of postoperative pain.Avenue Therapeutics Inc says ‍expect to report topline data in Q2 of 2018​.Avenue Therapeutics Inc - about 405 patients will be enrolled to IV tramadol 50 mg, IV tramadol 25 mg or placebo in a 1:1:1 ratio​.  Full Article

Fortress Biotech reports Q2 loss per share $0.43
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports second quarter 2017 financial results and recent corporate highlights.Q2 loss per share $0.43.Q2 revenue $50.7 million versus $2.2 million.  Full Article

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL